What happened with VRDN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Viridian Therapeutics is developing veligrotug and elegrobart to treat active and chronic thyroid eye disease. It has no medicines approved for sale and has never earned revenue from product sales. Future drug sales depend on completing development, obtaining regulatory approval, and securing patient access through insurance coverage and reimbursement.
Its revenue comes overwhelmingly from Kissei’s one-time upfront payment for exclusive rights to develop and sell these medicines in Japan. Viridian can also receive payments when agreed milestones are reached and royalties on Japanese sales. Kissei handles Japanese development, approval and commercialization; Viridian generally remains responsible for manufacturing and supply.
Viridian relies on outside manufacturers rather than making its medicines itself, with WuXi Biologics (Hong Kong) Limited its sole manufacturer of drug substance and finished drug product. Until product sales become substantial, it expects to fund operations through equity, debt and licensing or development agreements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Viridian's results hinge on thyroid eye disease (TED) drug approvals and adoption; watch Japan partner Kissei, which provided its $70 million in 2025 license revenue and could bring future milestones and royalties.
Amgen's Tepezza sales and new thyroid eye disease (TED) treatments directly challenge Viridian's veligrotug and elegrobart, which would compete for patients if approved. Amgen sells medicines through wholesalers and healthcare providers; watch its phase 3 trial of a wearable device that delivers Tepezza under the skin.
Immunovant challenges Viridian on two fronts: batoclimab competes with its TED candidates, while batoclimab and IMVT-1402 target FcRn and compete with its earlier drug pipeline. Immunovant has no revenue yet and needs approvals before it can sell medicines; watch batoclimab's phase 3 TED results.
argenx's marketed Vyvgart sets the efficacy and sales benchmarks for Viridian's competing FcRn-inhibitor pipeline. argenx sells it through its own sales teams in approved markets; sales for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy show the commercial bar Viridian would face.
Roivant Sciences controls Immunovant, so its exposure to Viridian's competition comes through Immunovant's development of TED treatments and FcRn therapies that rival Viridian's programs.
Novartis is developing TOUR006 as an injection under the skin for the same TED patients Viridian's antibody treatments target. The prescription-drug maker's phase 2b TOUR006 trial is the specific progress to watch, rather than its broad medicine sales.
Zai Lab develops and sells medicines in Greater China and now holds sublicensed rights to Viridian's non-cancer IGF-1R antibody products there, along with the manufacturing-development and supply agreement. Watch its progress with those products: Viridian can receive milestones and sales-based royalties, though Zenas remains responsible for paying the royalties.
Zenas BioPharma remains responsible for royalties owed to Viridian on its licensed non-cancer IGF-1R antibody products in Greater China, even after passing development, manufacturing and commercialization rights to Zai Lab. Sales of those licensed products—not Zenas's other drug programs—determine this royalty stream for Viridian.
Yarrow Bioscience holds rights outside China to GenSci098, an antibody targeting TSHR being developed for the same TED patients as Viridian's drugs. As of January 2026, its phase 1 TED trial was recruiting only in China and no anti-TSHR therapy was FDA-approved, making this an early-stage competitive threat.
Fed Interest Rate Decision
Viridian’s Fed-linked Prime Rate helps set interest on its Hercules loan, so rate changes can alter what the company pays to borrow, within the loan’s floor and cap.
Expected4.0%Last release4.0%
If it comes in above expectations
If the decision points to higher rates, the Prime-linked portion of Viridian’s loan interest may rise, increasing its borrowing costs; the 8.95% floor and 9.45% cap limit the change.
If it comes in below expectations
If the decision points to lower rates, the Prime-linked portion of Viridian’s loan interest may fall, reducing its borrowing costs; the 8.95% floor and 9.45% cap limit the change.
Amgen Inc earningsAMGN
Amgen's report shows how Tepezza is selling and whether its under-the-skin delivery device is advancing, both of which matter to Viridian's fight for TED patients.
Separate Tepezza sales from progress in the device trial. Strong sales show that an existing treatment is drawing patients and set a tougher market bar for Viridian; a successful device could make that treatment more convenient. Weaker sales would ease the immediate competitive pressure but would not, by itself, prove TED demand is weak; a device setback would reduce that potential convenience advantage. Together, these updates show whether Viridian faces a firmly established treatment or a rival that may become easier to use.
Viridian Therapeutics, Inc. earningsThis company
Viridian has no approved medicines or product-sales revenue, so this report shows whether its TED programs are advancing while its cash funds the work.
Read clinical or regulatory updates on both TED candidates alongside research spending and the cash balance. Progress with spending and cash that can support the work would show the programs remain financeable; delays alongside rising costs would thin the cash cushion and could bring forward the need for more funding. The question is whether progress is keeping pace with cash use.
Zai Lab Limited earningsZLAB
Zai Lab's report shows its progress developing Viridian-licensed antibody products and handling related manufacturing work in Greater China, a path to potential milestones and sales-based royalties for Viridian.
Watch for updates on Zai Lab's development and manufacturing work for these licensed products. Progress would bring them closer to potential milestones; if they are eventually approved and sold, Viridian is eligible for sales-based royalties paid through Zenas. If the programs or manufacturing work stall, that potential income remains further away. The key distinction is between Zai Lab advancing the work and Viridian already receiving revenue.
Immunovant, Inc. earningsIMVT
Immunovant's report shows whether its phase 3 TED treatment is progressing, bringing another potential rival closer to the patients Viridian is targeting.
Look for results or progress in batoclimab's phase 3 TED trial. Favorable evidence and continued progress would bring Immunovant closer to competing for the same patients, making the challenge to Viridian's candidates more direct; a setback or delay would ease that near-term pressure, but would not show that Viridian's drugs work. The takeaway is whether this rival is moving closer to patients.
